Voices of Biotech
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
- Sponsored Content
- Downstream Processing
BPI Contributor
October 14, 2020
20 Min View
Date: Oct 14, 2020
Duration: 20 Min
Sponsored by Cygnus Technologies
This webcast features: David Cetlin, Senior Director, R&D, Cygnus Technologies
As viruses can arise during the manufacture of biopharmaceuticals, regulatory agencies require viral clearance validation studies for each biopharmaceutical prior to approval. These studies are typically conducted in biosafety level (BSL)-2 facilities and require large capital and human resources. Due to these hurdles, process knowledge pertaining to viral clearance is limited during development and characterization.
The use of an accurate, economical, and quantifiable non-infectious viral surrogate would enable downstream purification scientists to study viral clearance throughout process development.
This webinar will explore the use of a BSL-1 compatible, non-infectious minute virus of mice (MVM) particles to predict viral clearance results over a wide variety of process development applications such as anion-exchange (AEX) design of experiments (DoE) study, ion-exchange (IEX) high-throughput screening, and downstream purification of an adenoassociated virus (AAV)-based viral vector.
Takeaways:
Viral clearance prediction is possible through the use of non-infectious surrogates such as MVM mock virus particles (MVM-MVPs) that mimic the physiochemical properties of live mammalian viruses.
MVM-MVPs can be applied to downstream efforts such as DoE and high-throughput screening and help facilitate process development/optimization.
AAVX resin (Thermo Fisher Scientific) was shown to be an effective viral clearance step within an AAV downstream purification process, and comparative MVM versus MVM-MVP data showed favorable prediction through the use of the non-infectious surrogate.
Watch the recorded webcast now.
About the Author(s)
You May Also Like
Upcoming Webcasts
Jun 17 - Jun 20, 2024
Jun 17 - Jun 20, 2024
Our Biopharmaceutical School is the perfect course to gain a well-rounded understanding of the Biopharmaceutical industry. Over three days, you will understand the principle steps in the biopharmaceutical lifecycle, including: raw material selection, up and downstream processes and core technology. Additionally, you will be familiarised with the latest industry trends, including Industry 4.0, and how these are likely to impact the industry’s evolution.
Through a combination of sessions led by experts from the likes of GSK and Pall Biotech, as well as group discussions with your peers, you will learn how to bring a biopharmaceutical drug to market. Each day will be chaired by a different member of the BioProcess International Academy faculty and there will also be time for networking and Q&As with the experts.
Learn More